| Popis: |
Lada Beara-Lasic1,3, Michael H Pillinger2,3, David S Goldfarb1,31Divisions of Nephrology and 2Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, USA; 3Department of Medicine, New York Harbor VA Health Care System, New York, NY, USAAbstract: Gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States (US). However, epidemiologic studies indicate that the quality of gout management is suboptimal owing to both patient and physician issues. Only three options for urate-lowering therapy are currently available in the US: allopurinol, probenecid, and recently, febuxostat. Probenecid is generally safe except for the occurrence of urolithiasis, but is only effective for the subset of patients with better kidney function. Allopurinol use is limited due to its side effects, potential toxicity of uncertain magnitude in patients with renal disease, and failure to achieve targeted serum urate levels. In part this failure may be due to the necessity for it to be titrated for optimal therapeutic effect. Febuxostat is a new medication that may offer several advantages and can be given as an alternative to allopurinol. We review the basic biology and clinical performance of febuxostat, and consider the potential utility of this agent in comparison to the older, better-established gout therapeutics.Keywords: allopurinol, gout suppressants, nephrolithiasis, uric acid, urolithiasis |
